{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-228150","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.117170+00:00","generated_at":"2026-06-30T00:56:15.158711+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted","bullets":["Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.","R&D expenses $62.0M (up from $54.1M) for start-up costs of Phase 3 trials and regulatory filings.","Completed NDA in U.S. and MAA in EU for mitapivat in adults with PK deficiency.","Chris Bowden to retire as CMO effective Sept 1; Sarah Gheuens to assume role.","Repurchased 10.5M shares for $529M at average price $50.41 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-228150","json":"https://secwatch.observer/filing/0001193125-21-228150.json","markdown":"https://secwatch.observer/filing/0001193125-21-228150.md","text":"https://secwatch.observer/filing/0001193125-21-228150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/0001193125-21-228150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/d108692d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:56:15.158711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a2a4ae41f","claim":"Christopher Bowden resigned as chief medical officer at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/0001193125-21-228150-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"chief medical officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}